Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEOBiotechnology
-$0.05 today
- Market cap
- $244.23M
- Beta
- 1.39
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.08
Volume 1.76M
Average 0.86M
LXEO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Lexeo Therapeutics, Inc. Common StockNASDAQ: LXEO
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $2.76M fell 25.5% year over year, behind the -19.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 1.5% from the prior quarter. Over 3 fiscal years it compounded at +89.6% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -25.5% toward the trailing-twelve-month pace of -19.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 12.13M USD
- Year-over-year change
- -2.7%
- 4-year CAGR
- +136.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.13M | -2.7% |
| FY2024 | 2024-12-31 | 12.47M | +309.9% |
| FY2023 | 2023-12-31 | 3.04M | +70.9% |
| FY2022 | 2022-12-31 | 1.78M | +361.4% |
| FY2021 | 2021-12-31 | 386K | — |
Stock-Based Compensation vs competitors
How LXEO compares with its peers on the latest reported figures
- LXEO's LTM Mar 2026 stock-based compensation of $11.19M is the 5th largest of the 11 companies compared; the peer median is $10.08M.
- Its year-over-year change of -19.1% is the 8th highest of 10, against a peer median of -8.6%.
- Over three fiscal years its annual growth of +89.6% compares with a peer median of +16.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.98B | +32410.1% | +56.9% | — | |
| LTM Mar 2026 | $14.34M | — | -14.0% | 1556.3% | |
| LTM Mar 2026 | $13.6M | -8.6% | +16.5% | 37.3% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $11.29M | +31.2% | +73.3% | — |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $11.19M | -19.1% | +89.6% | — |
| LTM Mar 2026 | $11.09M | +34.6% | +121.4% | — | |
| LTM Mar 2026 | $9.07M | -23.3% | -16.5% | 4.2% | |
| LTM Mar 2026 | $7.15M | -15.9% | +1.9% | — | |
| LTM Mar 2026 | $6.93M | -9.1% | +16.8% | 1385.0% | |
| LTM Mar 2026 | $5.99M | +37.2% | +2.3% | — | |
| LTM Mar 2026 | $3.95M | -191.3% | — | 1.8% | |
| Peer median (excluding LXEO) | $10.08M | -8.6% | +16.5% | 37.3% | |
Competitors are the stored peer set for LXEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (50.62M) | (59.28M) | (66.39M) | (98.33M) | (99.96M) |
| Depreciation & Amortization | 13K | 1.15M | 1.84M | 2M | 379K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 386K | 1.78M | 3.04M | 12.47M | 12.13M |
| Change in Working Capital | 6.04M | 1.79M | 1.48M | 2.73M | (9.52M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.02M | (426K) | (180K) | 2.38M | (1.56M) |
| Other Working Capital | 3.03M | 2.22M | 1.66M | 351K | (7.95M) |
| Other Non-Cash Items | 0 | 0 | 530K | (23K) | (1.6M) |
| Operating Cash Flow | (44.18M) | (54.56M) | (59.5M) | (81.15M) | (98.56M) |
| Capital Expenditures | (188K) | (901K) | (165K) | (481K) | (397K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (93.6M) | (195.4M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 105.53M |
| Other Investing Activities | 0 | (229K) | (50K) | 0 | 17K |
| Investing Cash Flow | (188K) | (901K) | (165K) | (94.08M) | (90.25M) |
| Debt Repayment | 0 | (163K) | 3.58M | (410K) | (533K) |
| Common Stock Issued | 170K | 332K | 100.25M | 88.71M | 217.33M |
| Common Stock Repurchased | 0 | 0 | 0 | (17K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (203K) | 332K | (35K) | 491K | 0 |
| Financing Cash Flow | 150.86M | 189K | 103.79M | 88.78M | 216.8M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 106.49M | (55.27M) | 44.13M | (86.45M) | 27.98M |
| Free Cash Flow | (44.37M) | (55.46M) | (59.66M) | (81.63M) | (98.96M) |
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
Intrinsic Alpha fair value
Locked
Current Price
$2.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.